Posted by Michael Wonder on 13 Aug 2024
Bavarian Nordic announces FDA acceptance and priority review of the BLA for its Chikungunya vaccine
13 August 2024 - PDUFA target action date of 14 February 2025.
Bavarian Nordic today announced that the US FDA has accepted and granted priority review for the biologics license application for CHIKV VLP, the Company’s vaccine candidate for immunisation to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.
